=======================================================
Advances in Cancer Therapies 2004
Oncology Research, Novel Biologics and Pharmacogenomics
=======================================================
15th and 16th September 2004, Workshop 14th September 2004
Hilton Kensington Hotel, London
**FINAL AGENDA BELOW - REQUEST YOUR BROCHURE TODAY**
Visiongain b2b Conferences is pleased to announce that 'Advances in Cancer Therapies 2004 - Oncology Research, Novel Biologics and Pharmacogenomics' will be run in mid September this year. This event will follow up on the success of 'Cancer Drugs 2003'. The agenda is nearing completion, now is your chance to register your interest in speaking, sponsoring or attending this leading event.
THEMES TO BE INCLUDED:
**Identify Key market Segments and Profit From Emerging Trends in Cancer Therapeutics
**Clinical Trials for Cancer- How can Your Company Bring a Drug to Trial and Advice on Overcome Delays
**Learn From the Best Practice Case Studies such as: Zometa- MabThera- Erbitux- ABX-EGF- Oncophage
**Examine Areas Shaping the Future of Cancer Therapies:
-Monoclonal Antibodies
-Antisense Drugs
-Vaccines
-Angiogenesis Inhibitors
**Pharmacogenomics - Assess the Advances in Personalisation of Cancer Therapies
**Discover how Alliances will Shape the Future of Cancer Therapy, Highlighting Opportunities
KEY SPEAKERS
** Dr. Bruno Osterwalder, VP, Global Head, Early & Strategic Oncology, Roche
** Dr. Peter Blume-Jensen, Head & Director, Molecular Oncology, Serono
** Dr. Jean-Francois Pouliot, Director of Scientific Research, Schering Plough
** Yong Jiang Hei, Senior Medical Brand Director - Zometa, Novartis
** Marty Duvall, VP, MAX Team Leader, Taxotere/New Cytotoxics, Global Medical and Marketing, Aventis Oncology
** Dr. Iris Kuss, COE Study Management Europe, Schering
** Caroline Turnbull, Arimidex Brand Leader, AstraZeneca
** Dr. Dimitris Voliotis, Director, Global Clinical Leader, Oncology, Bayer HealthCare
** Dr. Peter Bohlen, Senior VP, Research, ImClone Systems
** Dr. Raymond Withy, Chief Business Officer, Abgenix
** Dr. Nick Dean, Vice President Functional Genomics, Isis Pharmaceuticals
** Dr. Renu Gupta, Senior Vice President, Development, Antigenics
WHO SHOULD ATTEND THIS EVENT:
**Vice President, Clinical Oncology
**Director of Oncology Development
**Vice President of Clinical Research
**Program Director, Cancer
**Senior Director, Clinical Research
**Director, Experimental Medicine
**Medical Director
**Executive Director for Development
**Global Head of Oncology
-----------------------------------------------------------------
This event will also feature: Pre-conference Interactive Workshop
-----------------------------------------------------------------
**Strategies for Pricing and Market Access of New Oncology Drugs**
Tuesday 14th September 2004
Led by: Ulf Munack, Director, Simon-Kucher & Partners
This workshop will give you the opportunity to engage in knowledge-sharing with fellow professionals, which can result in brainstorming and creating ideas which you can use back in your own organisation.
You can gain a greater understanding of the pathology of pain, have detailed discussions about pain signalling pathways and ventures for new targets.
---------------------
DELEGATE REGISTRATION
---------------------
Places at this event are limited, please call or email me to secure your place.
- PRICING -
Attend the:
** Conference and pre conf. workshop GBP 1600.00 Plus VAT
** Conference only Fee: GBP 1299.00 Plus VAT
** Pre conference workshop only Fee: GBP 650.00 Plus VAT
- BOOKINGS -
Booking is easy, simply contact Christopher Cullinane on:
Telephone: +44 (0)20 8767 6711
Fax: +44 (0)20 8767 5001
Email: mailto:chris.cullinane@visiongain.com
Terms and conditions apply - see below.
If you have any further questions regarding this event and how you can be involved please do not hesitate to ask.
Kind regards,
Christopher Cullinane
Account Manager
Visiongain B2B Conferences
Telephone: +44 (0)20 8767 6711
Fax: +44 (0)20 8767 5001
Email: mailto:chris.cullinane@visiongain.com
******
AGENDA
******
PRE-CONFERENCE INTERACTIVE WORKSHOP
Strategies for Pricing and Market Access of New Oncology Drugs
Tuesday 14th September 2004
Led by: Ulf Munack, Director, Simon-Kucher & Partners
It is of most use to those who are willing and prepared to engage in meaningful discussions and network with others. This 'facilitated open-space' provides you with ideas and time to explore possible new targets of action and benchmark them against other approaches.
Main topics of discussion:
* P&R environment for cancer products in 2004
* Critical success factors for market access in oncology
* Examples of recent learning from new oncology launches
Schedule: The workshop will run from 10:00 until 14:00 with lunch and refreshments at appropriate intervals
DAY 1
WEDNESDAY 15TH SEPTEMBER
09:00 Registration and coffee
09:30 Opening remarks from the Chair
CLINICAL TRIALS IN CANCER
09:40 New Approaches to Clinical Development: Assess What Will Suit your Needs
* Maximum tolerated dose and biological effective dose: advice on maximising their use
* How to get accurate dose: response information
* How significant is shrinkage / no shrinkage to your clinical development? - Assess and implement
* Reliability of tumour markers - how far should you depend onthem? - Practical advice
* Assessment of combination therapy of new drugs with traditional ones - will it work for your drugs?
Dr. MariaGrazia Porro
Associate Director- Clinical Research/Oncology
Nerviano Medical Science
10:20 Signal Transduction-Based Drug Discovery: Oncogenic Kinase Signalling and Molecularly Targeted Therapeutics
* Major post-translational regulatory mechanisms -Reversible protein and lipid phosphorylation controlling cellfunction
* Causal involvement in human malignancies and immune disorders - perturbation of the normal regulatory mechanisms
controlling kinase and phosphatase activity
* Examples from Serono's kinase drug discovery program
* What are the major future challenges for kinase inhibitors as therapeutics? - How to overcome them
Dr. Peter Blume-Jensen
Head & Director, Molecular Oncology
Serono
11:00 Morning Coffee
11:20 Design, Interpretation and Outcomes of Phase IIa/IIb Trials in Oncology - The Clinical Perspective
* How to cope with the transition from phase I to II
* Objectives, endpoints, design and patient population
* What's different with targeted/ cytostatic vs cytotoxic compounds?
* Analysis of results and transition into phase III
Dr. Dimitris Voliotis
Director, Global Clinical Leader, Oncology
Bayer HealthCare
COMMERCIAL DEVELOPMENT: CASE STUDIES
12:00 CASE STUDY: Arimidex, A Novel Adjuvant Treatment for Early Breast Cancer in Postmenopausal Women
* Current market for breast cancer drugs - where can you capture a share?
* First and only aromatase inhibitor to be approved: potential within sector and market expectations
* Post marketing results: Belgium, Mexico and Japan - what to change and how to go about it
* New results: increased survival rate when taken after successful therapy with Taxotere or Nolvadex
Caroline Turnbull
Arimidex Brand Leader
AstraZeneca
12:40 Lunch
14:00 CASE STUDY: Zometa, the First Drug to be approved for Treating Bone Metastases from all solid tumors
* Causes of bone metastases: liquid tumours, solid tumours, side-effect and how to overcome them
* Zometa: a powerful version of Aredia? An update
* Safety and efficacy considerations - what Aventis has learnt
* Zometa for more tumour types - lungs, breast, prostate, multiple myeloma and renal
* Potential in market sector - pointers for share capture
Yong Jiang Hei
Senior Medical Brand Director, Zometa
Novartis
14:40 CASE STUDY: Taxotere, How it has Become the World's Largest Selling Breast Cancer Treatment
* Competitors in the field and how to keep the edge
* Market capture in other indications - non small cell lung cancer, gastric, ovarian and neck cancer
* FDA approved new indication - prostate cancer: the future for Taxotere?
* Methods used to establish Taxotere with clinicians - how to optimise market penetration
Marty Duvall
Vice-President, MAX Team Leader, Taxotere / New Cytotoxics
Global Medical and Marketing
Aventis Oncology
15:20 Afternoon Tea
15:40 CASE STUDY: Femara for Breast Cancer, How it will affect the Market
* Clinical results: reducing the recurrence of breast cancer by roughly 50%, post-therapy
* Ongoing product development strategies: clinical trials to efficacy data
* Current research goals: increasing efficacy and tolerability
* Future development opportunities: considering the way forward
Dr. Jean-Francois Pouliot
Director of Scientific Research
Schering Plough
MONOCLONAL ANTIBODY THERAPIES
16:20 CASE STUDY: ABX-EGF, the Monoclonal Antibody Generated by XenoMouse Technology
* Phase II clinical results: kidney, non-small cell lung, colorectal and prostate cancers
* XenoMouse technology - how can you use it to generate antibodies
* Key product characteristics: using differences between ABX-EGF and drugs targeting the EGF receptor and pathway
Dr. Raymond Withy
Chief Business Officer
Abgenix
17:00 Questions and Discussion
17:10 Summation of day one from conference chair
17:20 Close of Day One
DAY TWO
THURSDAY 16TH SEPTEMBER
09:00 Registration and Coffee
09:30 Opening remarks from the Chair
09:40 CASE STUDY: MabThera, the Primary Drug for Treatment of Non-Hodgkin Lymphoma
* Therapeutic work of MabThera - binding to CD20 antigen
* Breakdown of success in event - free survival in patients with aggressive non-Hodgkin lymphona
* New Indications: Rituxan for non-malignant autoimmune disorders?
* Results of ongoing trials - where have we succeeded and how
* Up and coming competitors to MabThera and strategies to maintain market lead
Dr. Bruno Osterwalder
VP, Global Head, Early & Strategic Oncology
Roche
10:20 CASE STUDY: Zevalin, A Novel Treatment Regime
Zevalin is the first product with a monoclonal antibody that is combined with a radioactive chemical for the treatment of non-Hodgkin lymphoma
* Two part administration of Zevalin: screening and treatment
* Results from Safety and Efficacy studies
* Toxicity of treatment - limiting use and how to overcome this
* How effective is it in patients who are refractory to antibody treatment?
Dr. Iris Kuss
COE Study Management Europe
Schering
11:00 Morning Coffee
NOVEL BIOLOGICS: ANTISENSE
11:20 How can You Get Antisense onto the Market
* Funding - driving Research and Development for the company
* Proprietary technologies - target validation made easier
* Isis' target validation intellectual property (IP) portfolio
* Established collaborations - help at hand
* Affinitak - progress to date, trials and results
* Future development opportunities: considering the way forward
Dr. Nick Dean
Vice President Functional Genomics
Isis Pharmaceuticals
NOVEL BIOLOGICS: VACCINES
12:00 CASE STUDY: Oncophage, the Invesigational Personalised Melanoma Vaccine
* Capturing the antigenic footprint- how to use this to control cancer
* Advantages over conventional treatment - no more debilitating side effects
* Fast track status - what will this mean to the market
* Ongoing product development strategies: clinical trials to efficacy data
Dr. Renu Gupta
Senior Vice President, Development
Antigenics
12:40 Lunch
NOVEL BIOLOGICS: ANGIOGENESIS INHIBITORS
14:00 CASE STUDY: Commercialisation of Thalidomide
* Proposed mechanism of Thalidomide action
* S.T.E.P.S: a unique distribution system
* The role of the independent investigator in clinical trials
* Thalidomide as a treatment for haematological and oncological conditions - is it effective?
* Clinical development of the ImiDs and SelCIDs
Dr. Jerome Zeldis
VP, Medical Affairs and Chief Medical Officer
Celgene Corporation
14:40 Anti-Angiogenic Strategies: Targeting the VEGF Receptors KDR and flt1
* Proteins and small molecules as anti-angiogenic agents
* Ongoing preclinical research - how to get it right
* KDR antibody phase I studies and efficacy in a leukemia model
* Therapeutic potential of VEGFR1 (flt1)
* VEGF receptor antibodies in a model of atherosclerosis
* Current research goals: increasing efficacy and tolerability
Dr. Peter Bohlen
Senior VP, Research
ImClone Systems
15:20 Afternoon Tea
PHARMACEUTICAL ALLIANCES
15:40 CASE STUDY: HAP Technology for Pharmaceutical Research
* DNA-based diagnostics and therapeutic products
- integrating genetic variation and population genomics
- developing, marketing and prescribing
* HAP database and DecoGen Informatics System
* STRENGTH study: AstraZeneca licensing agreement
Krishnan Nandabalan
VP Business Development
Genaissance
16:20 Big Pharma and Biotech Alliances: Perlegen Sciences Case Study
* Perlegen-identified single nucleotides: DNA scanning technology
* Genome scanning project: Bristol-Myers Squibb collaboration
* Benefits of scanning clinical trial participants
* Other collaborations
Paul Cusenza
Vice President, Alliance Management
Perlegen Sciences
17:00 Questions and Discussion
17:20 Chairman summation
17:30 Close of Conference
Terms & Conditions
NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below.
Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.
Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses.
To unsubscribe please reply with unsubscribe in the subject line.
Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. If you wish your details to be amended, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in the subject line. Please allow approximately 7 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect.
#####################################################################################
This email has been scanned by MailMarshal, an email content filter.
#####################################################################################
